Research Progress of Metformin in the Treatment of Non-alcoholic Fatty Liver Disease

Chengsheng Liu; Jiehua Xie

doi:doi:10.11648/j.abb.20200804.13

| Peer-Reviewed

Research Progress of Metformin in the Treatment of Non-alcoholic Fatty Liver Disease

Chengsheng Liu, Jiehua Xie

Published in Advances in Bioscience and Bioengineering (Volume 8, Issue 4)

Received: 6 December 2020 Accepted: 16 December 2020 Published: 22 December 2020

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Backgroud: Nonalcoholic fatty liver disease has become the second largest source of chronic liver disease in the urban population. Metformin, a traditional drug, has good prospects for treating the disease in primary health care facilities. Objective: To summarize and grasp the status of metformin in adults, children with diabetes and non-diabetic NAFLD patients. Methods: We reviewed 31 relevant research literatures in PubMed database, and sorted out some preclinical and clinical research results. Results: Metformin was found to have a good effect in improving liver function indicators in both adult diabetic and non-diabetic NAFLD patients, and could benefit liver histology in NAFLD patients with adult diabetes. Metformin treatment did not show a significant advantage over lifestyle interventions in children with NAFLD. Conclusion: Metformin can improve the liver function and histological structure of adult NAFLD patients to a certain extent, and children patients should still be treated mainly with improved lifestyle.

Published in	Advances in Bioscience and Bioengineering (Volume 8, Issue 4)
DOI	10.11648/j.abb.20200804.13
Page(s)	78-81
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2020. Published by Science Publishing Group

Keywords

Non-alcoholic Fatty Liver Disease, Metformin, Diabetes

References

[1]	Ross AB, Godin JP, Minehira K, et al. Increasing whole grain intake as part of prevention and treatment of nonalcoholic Fatty liver disease [J]. International journal of endocrinology 2013, 2013: 585876.
[2]	Amarapurkar DN, Hashimoto E, Lesmana LA, et al. How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences? [J]. Journal of gastroenterology and hepatology 2007, 22 (6): 788-793.
[3]	Paschos P, Paletas K. Non alcoholic fatty liver disease and metabolic syndrome [J]. Hippokratia 2009, 13 (1): 9-19.
[4]	Loomba R, Sirlin CB, Schwimmer JB, et al. Advances in pediatric nonalcoholic fatty liver disease [J]. Hepatology (Baltimore, Md) 2009, 50 (4): 1282-1293.
[5]	Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease [J]. Hepatology (Baltimore, Md) 2005, 41 (6): 1313-1321.
[6]	Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection [J]. Hepatology (Baltimore, Md) 2010, 51 (5): 1820-1832.
[7]	Day CP, James OF. Steatohepatitis: a tale of two "hits"? [J]. Gastroenterology 1998, 114 (4): 842-845.
[8]	Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association [J]. Hepatology (Baltimore, Md) 2012, 55 (6): 2005-2023.
[9]	Li Y, Xu S, Mihaylova MM, et al. AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice [J]. Cell metabolism 2011, 13 (4): 376-388.
[10]	Mazza A, Fruci B, Garinis GA, et al. The role of metformin in the management of NAFLD [J]. Experimental diabetes research 2012, 2012: 716404.
[11]	Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes [J]. Diabetes care 2009, 32 (1): 193-203.
[12]	Adler AI, Shaw EJ, Stokes T, et al. Newer agents for blood glucose control in type 2 diabetes: summary of NICE guidance [J]. BMJ (Clinical research ed) 2009, 338: b1668.
[13]	Mantovani A, Byrne CD, Scorletti E, Mantzoros CS, Targher G. Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials [J]. Diabetes Metab. 2020; 46 (6): 427-441.
[14]	Angulo P, Kleiner D. E, Dam-Larsen S. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease [J]. Gastroenterology. 2015; 149 (e310): 389-397.
[15]	Barbero-Becerra VJ, Santiago-Hernandez JJ, Villegas-Lopez FA, et al. Mechanisms involved in the protective effects of metformin against nonalcoholic fatty liver disease [J]. Current medicinal chemistry 2012, 19 (18): 2918-2923.
[16]	Viollet B, Guigas B, Sanz Garcia N, et al. Cellular and molecular mechanisms of metformin: an overview [J]. Clinical science (London, England: 1979) 2012, 122 (6): 253-270.
[17]	Huypens P, Quartier E, Pipeleers D, et al. Metformin reduces adiponectin protein expression and release in 3T3-L1 adipocytes involving activation of AMP activated protein kinase [J]. European journal of pharmacology 2005, 518 (2-3): 90-95.
[18]	Kita Y, Takamura T, Misu H, et al. Metformin prevents and reverses inflammation in a non-diabetic mouse model of nonalcoholic steatohepatitis [J]. PloS one 2012, 7 (9): e43056.
[19]	Garinis GA, Fruci B, Mazza A, et al. Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study [J]. International journal of obesity (2005) 2010, 34 (8): 1255-1264.
[20]	Haukeland JW, Konopski Z, Eggesbø HB, et al. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial [J]. Scandinavian journal of gastroenterology 2009, 44 (7): 853-860.
[21]	Loomba R, Lutchman G, Kleiner DE, et al. Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis [J]. Alimentary pharmacology & therapeutics 2009, 29 (2): 172-182.
[22]	Shields WW, Thompson KE, Grice GA, et al. The Effect of Metformin and Standard Therapy versus Standard Therapy alone in Nondiabetic Patients with Insulin Resistance and Nonalcoholic Steatohepatitis (NASH): A Pilot Trial [J]. Therapeutic advances in gastroenterology 2009, 2 (3): 157-163.
[23]	Tiikkainen M, Häkkinen AM, Korsheninnikova E, et al. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes [J]. Diabetes 2004, 53 (8): 2169-2176.
[24]	Nair S, Diehl AM, Wiseman M, et al. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial [J]. Alimentary pharmacology & therapeutics 2004, 20 (1): 23-28.
[25]	Bugianesi E, Gentilcore E, Manini R, et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease [J]. The American journal of gastroenterology 2005, 100 (5): 1082-1090.
[26]	Chen HP, Shieh JJ, Chang CC, et al. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies [J]. Gut 2013, 62 (4): 606-615.
[27]	Lin CH, Kohli R. Emerging New Diagnostic Modalities and Therapies of Nonalcoholic Fatty Liver Disease [J]. Curr Gastroenterol Rep. 2020; 22 (10): 52.
[28]	Geng Y, Hernandez Villanueva A, Oun A, Buist-Homan M, Blokzijl H, Faber KN, et al. Protective effect of metformin against palmitate-induced hepatic cell death [J]. Biochim Biophys Acta Mol Basis Dis. 2020; 1866 (3): 165621.
[29]	Lavine JE, Schwimmer JB, Van Natta ML, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial [J]. Jama 2011, 305 (16): 1659-1668.
[30]	Omer Z, Cetinkalp S, Akyildiz M, et al. Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease [J]. European journal of gastroenterology & hepatology 2010, 22 (1): 18-23.

Cite This Article

Plain Text BibTeX RIS

APA Style

Chengsheng Liu, Jiehua Xie. (2020). Research Progress of Metformin in the Treatment of Non-alcoholic Fatty Liver Disease. Advances in Bioscience and Bioengineering, 8(4), 78-81. https://doi.org/10.11648/j.abb.20200804.13

Copy | Download

ACS Style

Chengsheng Liu; Jiehua Xie. Research Progress of Metformin in the Treatment of Non-alcoholic Fatty Liver Disease. Adv. BioSci. Bioeng. 2020, 8(4), 78-81. doi: 10.11648/j.abb.20200804.13

Copy | Download

AMA Style

Chengsheng Liu, Jiehua Xie. Research Progress of Metformin in the Treatment of Non-alcoholic Fatty Liver Disease. Adv BioSci Bioeng. 2020;8(4):78-81. doi: 10.11648/j.abb.20200804.13

Copy | Download

@article{10.11648/j.abb.20200804.13,
  author = {Chengsheng Liu and Jiehua Xie},
  title = {Research Progress of Metformin in the Treatment of Non-alcoholic Fatty Liver Disease},
  journal = {Advances in Bioscience and Bioengineering},
  volume = {8},
  number = {4},
  pages = {78-81},
  doi = {10.11648/j.abb.20200804.13},
  url = {https://doi.org/10.11648/j.abb.20200804.13},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.abb.20200804.13},
  abstract = {Backgroud: Nonalcoholic fatty liver disease has become the second largest source of chronic liver disease in the urban population. Metformin, a traditional drug, has good prospects for treating the disease in primary health care facilities. Objective: To summarize and grasp the status of metformin in adults, children with diabetes and non-diabetic NAFLD patients. Methods: We reviewed 31 relevant research literatures in PubMed database, and sorted out some preclinical and clinical research results. Results: Metformin was found to have a good effect in improving liver function indicators in both adult diabetic and non-diabetic NAFLD patients, and could benefit liver histology in NAFLD patients with adult diabetes. Metformin treatment did not show a significant advantage over lifestyle interventions in children with NAFLD. Conclusion: Metformin can improve the liver function and histological structure of adult NAFLD patients to a certain extent, and children patients should still be treated mainly with improved lifestyle.},
 year = {2020}
}

Copy | Download

TY  - JOUR
T1  - Research Progress of Metformin in the Treatment of Non-alcoholic Fatty Liver Disease
AU  - Chengsheng Liu
AU  - Jiehua Xie
Y1  - 2020/12/22
PY  - 2020
N1  - https://doi.org/10.11648/j.abb.20200804.13
DO  - 10.11648/j.abb.20200804.13
T2  - Advances in Bioscience and Bioengineering
JF  - Advances in Bioscience and Bioengineering
JO  - Advances in Bioscience and Bioengineering
SP  - 78
EP  - 81
PB  - Science Publishing Group
SN  - 2330-4162
UR  - https://doi.org/10.11648/j.abb.20200804.13
AB  - Backgroud: Nonalcoholic fatty liver disease has become the second largest source of chronic liver disease in the urban population. Metformin, a traditional drug, has good prospects for treating the disease in primary health care facilities. Objective: To summarize and grasp the status of metformin in adults, children with diabetes and non-diabetic NAFLD patients. Methods: We reviewed 31 relevant research literatures in PubMed database, and sorted out some preclinical and clinical research results. Results: Metformin was found to have a good effect in improving liver function indicators in both adult diabetic and non-diabetic NAFLD patients, and could benefit liver histology in NAFLD patients with adult diabetes. Metformin treatment did not show a significant advantage over lifestyle interventions in children with NAFLD. Conclusion: Metformin can improve the liver function and histological structure of adult NAFLD patients to a certain extent, and children patients should still be treated mainly with improved lifestyle.
VL  - 8
IS  - 4
ER  -

Copy | Download

Author Information

Chengsheng Liu

Health Center of Huashan Town, Guangzhou, China
Jiehua Xie

District Center for Disease Control and Prevention, Guangzhou, China

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Chengsheng Liu, Jiehua Xie. (2020). Research Progress of Metformin in the Treatment of Non-alcoholic Fatty Liver Disease. Advances in Bioscience and Bioengineering, 8(4), 78-81. https://doi.org/10.11648/j.abb.20200804.13

Copy | Download

ACS Style

Chengsheng Liu; Jiehua Xie. Research Progress of Metformin in the Treatment of Non-alcoholic Fatty Liver Disease. Adv. BioSci. Bioeng. 2020, 8(4), 78-81. doi: 10.11648/j.abb.20200804.13

Copy | Download

AMA Style

Chengsheng Liu, Jiehua Xie. Research Progress of Metformin in the Treatment of Non-alcoholic Fatty Liver Disease. Adv BioSci Bioeng. 2020;8(4):78-81. doi: 10.11648/j.abb.20200804.13

Copy | Download

@article{10.11648/j.abb.20200804.13,
  author = {Chengsheng Liu and Jiehua Xie},
  title = {Research Progress of Metformin in the Treatment of Non-alcoholic Fatty Liver Disease},
  journal = {Advances in Bioscience and Bioengineering},
  volume = {8},
  number = {4},
  pages = {78-81},
  doi = {10.11648/j.abb.20200804.13},
  url = {https://doi.org/10.11648/j.abb.20200804.13},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.abb.20200804.13},
  abstract = {Backgroud: Nonalcoholic fatty liver disease has become the second largest source of chronic liver disease in the urban population. Metformin, a traditional drug, has good prospects for treating the disease in primary health care facilities. Objective: To summarize and grasp the status of metformin in adults, children with diabetes and non-diabetic NAFLD patients. Methods: We reviewed 31 relevant research literatures in PubMed database, and sorted out some preclinical and clinical research results. Results: Metformin was found to have a good effect in improving liver function indicators in both adult diabetic and non-diabetic NAFLD patients, and could benefit liver histology in NAFLD patients with adult diabetes. Metformin treatment did not show a significant advantage over lifestyle interventions in children with NAFLD. Conclusion: Metformin can improve the liver function and histological structure of adult NAFLD patients to a certain extent, and children patients should still be treated mainly with improved lifestyle.},
 year = {2020}
}

Copy | Download

TY  - JOUR
T1  - Research Progress of Metformin in the Treatment of Non-alcoholic Fatty Liver Disease
AU  - Chengsheng Liu
AU  - Jiehua Xie
Y1  - 2020/12/22
PY  - 2020
N1  - https://doi.org/10.11648/j.abb.20200804.13
DO  - 10.11648/j.abb.20200804.13
T2  - Advances in Bioscience and Bioengineering
JF  - Advances in Bioscience and Bioengineering
JO  - Advances in Bioscience and Bioengineering
SP  - 78
EP  - 81
PB  - Science Publishing Group
SN  - 2330-4162
UR  - https://doi.org/10.11648/j.abb.20200804.13
AB  - Backgroud: Nonalcoholic fatty liver disease has become the second largest source of chronic liver disease in the urban population. Metformin, a traditional drug, has good prospects for treating the disease in primary health care facilities. Objective: To summarize and grasp the status of metformin in adults, children with diabetes and non-diabetic NAFLD patients. Methods: We reviewed 31 relevant research literatures in PubMed database, and sorted out some preclinical and clinical research results. Results: Metformin was found to have a good effect in improving liver function indicators in both adult diabetic and non-diabetic NAFLD patients, and could benefit liver histology in NAFLD patients with adult diabetes. Metformin treatment did not show a significant advantage over lifestyle interventions in children with NAFLD. Conclusion: Metformin can improve the liver function and histological structure of adult NAFLD patients to a certain extent, and children patients should still be treated mainly with improved lifestyle.
VL  - 8
IS  - 4
ER  -

Copy | Download